Oncology News | pharmaphorum

News

AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.

News

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.

News

Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.

News

Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.